A Phase 1, First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 208 in Adult Subjects with Advanced Solid Tumours.
Phase of Trial: Phase I
Latest Information Update: 18 Dec 2014
At a glance
- Drugs AMG 208 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Biomarker; Pharmacokinetics; Therapeutic Use
- Sponsors Amgen
- 10 Jun 2017 Biomarkers information updated
- 15 Dec 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 15 Jan 2014 Planned End Date changed from 1 Oct 2013 to 1 Nov 2014 as reported by ClinicalTrials.gov record.